Belite Bio Begins Rolling NDA for STGD1 Drug Tinlarebant, Completes Enrollment for Two Phase 3 Trials
BLTE has more than doubled off its 52-week low of $56.1.
Summary
Belite Bio announced its unaudited first quarter 2026 financial results and a significant corporate update. Most notably, the company initiated a rolling New Drug Application (NDA) submission to the FDA in April 2026 for tinlarebant, its lead drug candidate for Stargardt disease (STGD1), with full submission anticipated in Q2 2026. This is a critical step towards potential market approval and commercialization for a drug with Breakthrough Therapy designation. Furthermore, Belite Bio completed enrollment for two other pivotal Phase 3 trials: the DRAGON II trial for adolescent STGD1 patients and the PHOENIX trial for Geographic Atrophy (GA) patients. These clinical and regulatory milestones represent substantial progress for Belite Bio and are highly material for a clinical-stage biotechnology company.
At the time of this announcement, BLTE was trading at $139.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $56.10 to $200.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.